We are happy to share a milestone moment for INNOVOTEX and our mission to transform cancer therapy.
INNOVOTEX INC. was selected as a finalist at the Houston Innovation Award event sponsored by Boehringer Ingelheim and Portal Innovations.
The Houston Innovation Award highlights emerging life science companies pioneering the next generation of therapeutics. Competing alongside an exceptional cohort of innovators, our team was honored to present our work advancing NOVO-111 from our first-in-class therapeutic platform designed to overcome the limitations of both traditional platinum chemotherapy and antibody-based treatments.
We are deeply grateful to the organizers, mentors, and participants for the valuable feedback, networking opportunities, and support that continue to shape our development path.
These partnerships exemplify the collaborative spirit needed to bring groundbreaking therapies to patients. As we move NOVO-111 toward IND-enabling studies and clinical development, INNOVOTEX remains committed to building strategic alliances that accelerate innovation and impact.
Together, we’re redefining what’s possible in cancer treatment.